Journal ArticleOPEN ACCESS

More Sound Cancer Therapy Biomarker Development With Active Noise Control

  • Maitland M
The Oncologist (2013) 18(3) 239-241
DOI: 10.1634/theoncologist.2013-0030
2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This commentary discusses the use of blood pressure (BP) as a biomarker. It is argued that typical office BP measurements are not qualified as predictive markers for bevacizumab therapy because they were never validated. Better validated biomarkers for qualification testing in phase III trials are needed.

Cite

CITATION STYLE

APA

Maitland, M. L. (2013). More Sound Cancer Therapy Biomarker Development With Active Noise Control. The Oncologist, 18(3), 239–241. https://doi.org/10.1634/theoncologist.2013-0030

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free